China's Tasly Pharm H1 profit up 24%
Updated: 2014-08-11 10:21
(Xinhua)
|
|||||||||||
BEIJING - Tasly Pharmaceutical Group Co Ltd, a leading pharmaceutical company in China, said Saturday that its net profit in the first half of the year rose 24.04 percent year on year to 744.5 million yuan ($120.9 million).
Business revenues rose 13.07 percent from a year earlier to 6.1 billion yuan, according to the company's interim report.
Earning per share for the period stood at 0.72 yuan.
Tasly is one of China's largest producers of traditional Chinese medicines. Its business scope also includes chemical and biological drugs, healthcare products, and functional foods.
Pharmaceutical sector ripe for innovation |
|
Today's Top News
Beijing 'open' to US airstrikes in Iraq
BMW to reduce prices amid probe
Foreigners jailed for prying data
Chinese thriller breaks stereotype
Russia bans West food, Brazil benefits
Russia to ban food imports from EU, US
Obama authorizes airstrikes in Iraq
Snowden extends Russian stay
Hot Topics
Lunar probe , China growth forecasts, Emission rules get tougher, China seen through 'colored lens', International board,
Editor's Picks
Horrific nightmare at Kunshan factory |
Shaolin: Fists of fame |
Reading into an online age |
China helps fight international war on drugs |
Crackdown on terrorist attacks |
My China Story: Meeting the master |